MX2016002078A - Derivados de 1h-pirazolo[3,4]piridina y composiciones farmaceuticas de los mismos para el tratamiento de trastornos proliferativos. - Google Patents

Derivados de 1h-pirazolo[3,4]piridina y composiciones farmaceuticas de los mismos para el tratamiento de trastornos proliferativos.

Info

Publication number
MX2016002078A
MX2016002078A MX2016002078A MX2016002078A MX2016002078A MX 2016002078 A MX2016002078 A MX 2016002078A MX 2016002078 A MX2016002078 A MX 2016002078A MX 2016002078 A MX2016002078 A MX 2016002078A MX 2016002078 A MX2016002078 A MX 2016002078A
Authority
MX
Mexico
Prior art keywords
treatment
diseases
pharmaceutical compositions
prophylaxis
pyrazolo
Prior art date
Application number
MX2016002078A
Other languages
English (en)
Inventor
Laurent Raymond Maurice Sanière
Jacques Huck
Graeme James Dykes
Benoît Antoine Schmitt
Javier Blanc
Anna Sara Butler
Stéphane Nicolas Alain Beaumont
Florence Marie-Emilie Bonnaterre
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of MX2016002078A publication Critical patent/MX2016002078A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con compuestos de acuerdo con la fórmula I: en donde R1, R2, R3, R4, L y X son como se definen en la presente. La presente invención se relaciona con compuestos, métodos para su producción, composiciones farmacéuticas que los comprenden y su uso en la prevención y/o el tratamiento de afecciones inflamatorias, diabetes de tipo 2, enfermedades neurológicas y/o neurodegenerativas, enfermedades autoinmunes, enfermedades proliferativas (en particular, enfermedades metastásicas, y/o cáncer), enfermedades asociadas con angiogénesis anormal, degradación de cartílago e/o interrupción de homeostasis de cartílagos, en particular en la prevención y/o el tratamiento de cáncer. La presente invención también describe métodos de tratamiento usando los mismos compuestos, para la prevención y/o el tratamiento de tales enfermedades por administración del compuesto de la invención.
MX2016002078A 2013-08-23 2014-08-18 Derivados de 1h-pirazolo[3,4]piridina y composiciones farmaceuticas de los mismos para el tratamiento de trastornos proliferativos. MX2016002078A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1315072.7A GB201315072D0 (en) 2013-08-23 2013-08-23 Novel compounds and pharmaceutical compositions thereoffor the treatment of proliferative disorders
PCT/EP2014/067574 WO2015024905A1 (en) 2013-08-23 2014-08-18 Derivatives of 1 h-pyrazolo[3,4-b]pyridine and pharmaceutical compositions thereof for the treatment of proliferative disorders

Publications (1)

Publication Number Publication Date
MX2016002078A true MX2016002078A (es) 2016-06-23

Family

ID=49302102

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002078A MX2016002078A (es) 2013-08-23 2014-08-18 Derivados de 1h-pirazolo[3,4]piridina y composiciones farmaceuticas de los mismos para el tratamiento de trastornos proliferativos.

Country Status (16)

Country Link
US (1) US9062051B2 (es)
EP (1) EP3036234A1 (es)
JP (1) JP2016528269A (es)
KR (1) KR20160040301A (es)
CN (1) CN105473590A (es)
AR (1) AR097339A1 (es)
AU (1) AU2014310652A1 (es)
BR (1) BR112016002872A2 (es)
CA (1) CA2920991A1 (es)
GB (1) GB201315072D0 (es)
IL (1) IL243739A0 (es)
MX (1) MX2016002078A (es)
PH (1) PH12016500173A1 (es)
SG (1) SG11201601157XA (es)
TW (1) TW201536783A (es)
WO (1) WO2015024905A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111620868B (zh) * 2020-05-28 2021-08-31 爱斯特（成都）生物制药股份有限公司 一种1H-吡唑并[3,4-b]吡啶-3-甲醛的制备方法
EP4215533A1 (en) * 2020-09-16 2023-07-26 Axceso Biopharma Co., Ltd. Pyrimidopyrimidinone compound and pharmaceutical composition comprising same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100113415A1 (en) * 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
US8846673B2 (en) * 2009-08-11 2014-09-30 Bristol-Myers Squibb Company Azaindazoles as kinase inhibitors and use thereof
KR20130077390A (ko) * 2011-12-29 2013-07-09 제이더블유중외제약 주식회사 단백질 키나아제 저해활성을 가지는 6-아미노-3-카복스아미도인다졸 유도체

Also Published As

Publication number Publication date
KR20160040301A (ko) 2016-04-12
IL243739A0 (en) 2016-04-21
AU2014310652A1 (en) 2016-03-03
PH12016500173A1 (en) 2016-04-25
JP2016528269A (ja) 2016-09-15
CN105473590A (zh) 2016-04-06
EP3036234A1 (en) 2016-06-29
BR112016002872A2 (pt) 2017-08-01
US9062051B2 (en) 2015-06-23
WO2015024905A1 (en) 2015-02-26
TW201536783A (zh) 2015-10-01
US20150080391A1 (en) 2015-03-19
AR097339A1 (es) 2016-03-09
GB201315072D0 (en) 2013-10-02
SG11201601157XA (en) 2016-03-30
CA2920991A1 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
PH12017501661A1 (en) 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
MY170260A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GEP201706659B (en) Novel bicyclic pyridinones
PH12015501289B1 (en) Novel benzimidazole derivatives as ep4 antagonists
MY174897A (en) Anti-fibrotic pyridinones
MX347917B (es) Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
MX2010007683A (es) Derivados heterociclicos fusionados y metodos de uso como inhibidores de c-met.
IN2014DN09352A (es)
IN2014DN09348A (es)
MX2014000779A (es) Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide.
MY189764A (en) 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as adamts inhibitors for the treatment of osteoarthritis
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
TN2014000112A1 (en) Ep1 receptor ligands
PH12018500827A1 (en) 6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-b]pyridin-3-yl]-nicotinonitrile derivatives and their use as irak inhibitors
PH12019502823A1 (en) Pyrrolopyrimidine and pyrrolopyridine derivatives
IN2014DN09347A (es)
PH12018500650A1 (en) New imidazo [4,5-b] pyridine derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12015500310A1 (en) Pyrrolopyrazoles as n-type calcium channel blockers
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX2019011265A (es) Derivados del acido acetico azaindol y su uso como moduladores de receptor de prostaglandina d2.
PH12016500173A1 (en) Derivatives of 1 h-pyrazolo[3,4-b]pyridine and pharmaceutical compositions thereof for the treatment of proliferative disorders
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).
MX2014003584A (es) Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides.
PH12015500314A1 (en) Cyclopentylpyrazoles as n-type calcium channel blockers
MX2016011900A (es) Derivados de acido azaindol-acetico y su uso como moduladores del receptor de prostaglandina d2.